Late-Stage Active Oncology Drug Developers | An Overview
June 22, 2024
. NON-RECEPTOR TYROSINE KINASE INHIBITORS 1. Bcr-Abl1 Inhibitors 2. JAK Inhibitors 3. BTK Inhibitors Check Also KINASE INHIBITORS - An...
Protein kinases are the enzymes that catalyzes the transfer of γ-phosphate group from ATP to protein residues containing hydroxyl groups...
Protein kinases are the enzymes that catalyzes the transfer of γ-phosphate group from ATP to protein residues containing hydroxyl groups...
Top 15 Pharma Companies alone comprise of more than 10% of Oncology Drug Development worldwide.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.Articles in this...
EEpigenetics is a branch of genetics that studies the heritable changes of gene expression without changing the nucleotide sequence of...
EEpigenetics is a branch of genetics that studies the heritable changes of gene expression without changing the nucleotide sequence of...
First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...
First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...
NK is the abbreviation of Natural Killer, and its Chinese name is natural killer cell. Due to the pan-specific...
Read moreupdated.. easy.. precise... complete...
Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.
LEARN MORE »
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.